At 10:28 IST, the barometer index, the S&P BSE Sensex, was down 687.03 points or 1.18% to 57,302.87. The Nifty 50 index lost 203.35 points or 1.19% to 16,896.70.
In the broader market, the S&P BSE Mid-Cap index fell 1.33% while the S&P BSE Small-Cap index slipped 1.07%.
The market breadth was weak. On the BSE, 969 shares rose and 2,215 shares fell. A total of 150 shares were unchanged.
Foreign portfolio investors (FPIs) sold shares worth Rs 1,766.53 crore, while domestic institutional investors (DIIs), were net buyers to the tune of Rs 1,817.14 crore in the Indian equity market on 17 March, provisional data showed.
Investors are cautious ahead of the US Federal Reserve's meeting outcome later this week, to see how the central bank will proceed in its fight against inflation in light of the shakeup in the banking sector.
Buzzing Index:
The Nifty Metal index lost 2.31% to 5,473.10. The index advanced 2.39% in the past trading session.
National Aluminium Company (down 4.45%), Adani Enterprises (down 3.6%), Steel Authority of India (down 2.99%), Hindalco Industries (down 2.66%), Jindal Stainless (down 2.52%), Hindustan Copper (down 2.4%), Vedanta (down 1.92%), Jindal Steel & Power (down 1.77%), Ratnamani Metals & Tubes (down 1.66%) and Tata Steel (down 1.59%) declined.
Stocks in Spotlight:
Can Fin Homes fell 2.29%. Suresh Srinivasan Iyer is appointed as the managing director and CEO with effect from 18 March 2023, initially for a fixed term of three years and further extendable to two years. Further, the board has renewed the authorisations for issuance of non-convertible redeemable debentures upto an amount of Rs 1,764 crore, on private placement basis, in one or more tranches, for a period upto the date of the annual general meeting (AGM) of the year 2022-23.
Tata Steel declined 1.59%. The company announced that it has acquired 1,55,34,738 equity shares of its wholly owned subsidiary, Tata Steel Advanced Materials (TSAML) for an amount aggregating to approximately Rs 19.90 crore.
Glenmark Pharmaceuticals shed 0.33%. The pharma company said that it has received final approval by the United States Food & Drug Administration (US FDA) for Prochlorperazine Maleate tablets, the generic version of Compazine tablets of GlaxoSmithKline. Prochlorperazine is used in the treatment of nausea, vomiting, and migraine caused by various conditions.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
